Welcome to our dedicated page for JUPITER NEUROSCIENCES SEC filings (Ticker: JUNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jupiter Neurosciences, Inc. filings document a clinical-stage pharmaceutical issuer with common stock listed on the Nasdaq Capital Market and a business built around the JOTROL™ resveratrol platform and Nugevia™ products. Material-event reports cover standby equity purchase and registration-rights agreements, convertible promissory notes, amendments to installment provisions, and Nasdaq continued-listing notices.
Proxy materials disclose annual meeting matters, board governance and stockholder voting procedures. Rule 12b-25 notices document delayed periodic reports for annual and quarterly filings, while capital-structure disclosures address common stock, potential share issuances and related financing limitations.
JUPITER NEUROSCIENCES, INC. director Tomas Jan Philipson received a grant of stock options as board compensation. He was awarded 536,428 stock options, each for one share of common stock at an exercise price of $0.21 per share. Of this grant, 90,000 options relate to his appointment to the Board of Directors, and 446,428 options were granted instead of cash for his annual board retainer and committee fees. The options vest in 12 equal quarterly installments beginning on September 2, 2026, as long as he continues to serve as a director through each vesting date, and are scheduled to expire on June 29, 2036.
JUPITER NEUROSCIENCES, INC. director Tomas Jan Philipson filed an initial Form 3 reporting his status as a director and not a ten percent owner. The filing shows no insider transactions, exercises, gifts, or tax withholdings and provides no derivative holdings information at this time.
Jupiter Neurosciences, Inc. filed a prospectus supplement dated June 30, 2026 that incorporates a Form 8-K reporting the appointment of Tomas J. Philipson, Ph.D. to the Board effective June 26, 2026.
The Board named Dr. Philipson to the Audit and Compensation Committees. In lieu of cash, Dr. Philipson will receive a sign-on option for 90,000 shares and an option in lieu of annual cash retainer for 446,428 shares, each vesting quarterly over 36 months with a Grant Date of June 29, 2026. Shares trade on Nasdaq under JUNS; closing price was $0.21 on June 29, 2026.
Jupiter Neurosciences appointed Tomas J. Philipson, Ph.D., a 64-year-old health care economist with extensive academic, government, and industry experience, to its Board of Directors effective June 26, 2026. He will serve until the next annual stockholder meeting, unless he departs earlier.
He was also appointed to the Board’s Audit Committee and Compensation Committee. In lieu of standard cash fees for non-employee directors, he will receive stock options, aligning his compensation with the company’s long-term performance.
Jupiter Neurosciences, Inc. is registering 16,000,000 shares of common stock for resale by YA II PN, LTD (Yorkville) under a Standby Equity Purchase Agreement (SEPA). These “Advance Shares” may be issued at Jupiter’s discretion through one or more Advances.
The SEPA provides up to $20.0 million in potential equity financing, of which $2.8 million has already been raised through earlier sales and related convertible notes. As of June 17, 2026, Jupiter had 48,224,110 shares outstanding; if all 16,000,000 registered shares were issued, they would represent about 24.9% of total shares and 31.6% of non‑affiliate shares, meaning meaningful potential dilution to existing holders.
Jupiter is a clinical-stage pharmaceutical company developing JOTROL™, an enhanced resveratrol formulation targeting central nervous system disorders including Parkinson’s disease, and commercializing its Nugevia™ longevity and wellness supplement line. The company expects SEPA proceeds to primarily support a Phase 2 Parkinson’s trial, expand direct‑to‑consumer Nugevia marketing, and fund general corporate purposes.
Jupiter Neurosciences is calling a virtual annual meeting on July 22, 2026 to vote on key governance items. Stockholders will elect seven directors, including two new nominees, and ratify Cherry Bekaert LLP as auditor for the year ending December 31, 2026.
They will also vote on increasing the 2025 Equity Incentive Plan share pool by 5,250,000 common shares and on a reverse stock split at a ratio between 1:10 and 1:100, with the exact ratio and timing left to the board’s discretion. The proxy details director independence, committee structures, and 2025 executive pay, including equity awards tied to the 2024 IPO and prior salary reductions.
Jupiter Neurosciences, Inc. filed a Prospectus Supplement No. 6 to its Registration Statement (No. 333-291832) dated June 22, 2026, which incorporates its Form 8-K dated June 17, 2026. The Form 8-K reports that director Allison W. Brady resigned from the Board and from the Audit and Compensation Committees, effective June 17, 2026. Her Board seat will remain vacant until the annual meeting on July 22, 2026. The supplement references the Prospectus dated December 11, 2025 and notes the company’s Nasdaq symbol JUNS and a closing share price of $0.2380 on June 18, 2026.
Jupiter Neurosciences, Inc. reported that board member Allison W. Brady resigned from the Board of Directors on June 17, 2026, effective immediately. She also stepped down from the Board’s Audit Committee and Compensation Committee on the same date. The company states that her decision to resign was not due to any disagreement regarding operations, policies, or practices. The Board seat will remain vacant until the company’s annual meeting scheduled for July 22, 2026.